XML 13 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Noncontrolling Interest
Beginning Balance at Dec. 31, 2024 $ 202,485 $ 14 $ 1,506,353 $ 166 $ (1,303,824) $ (224)
Beginning Balance, Shares at Dec. 31, 2024   147,773,744        
Issuance of common stock for cash upon exercise of stock options 7,061 $ 1 7,060      
Issuance of common stock for cash upon exercise of stock options, Shares   1,120,704        
Vesting of restricted stock units and market-based restricted stock units   3,340,324        
Share-based compensation expense 25,506   25,506      
Other comprehensive loss (93)     (93)    
Net (loss) income (55,423)       (55,466) 43
Ending Balance at Jun. 30, 2025 179,536 $ 15 1,538,919 73 (1,359,290) (181)
Ending Balance, Shares at Jun. 30, 2025   152,234,772        
Beginning Balance at Mar. 31, 2025 190,221 $ 15 1,523,950 134 (1,333,676) (202)
Beginning Balance, Shares at Mar. 31, 2025   151,916,722        
Issuance of common stock for cash upon exercise of stock options 1,610   1,610      
Issuance of common stock for cash upon exercise of stock options, Shares   238,211        
Vesting of restricted stock units   79,839        
Share-based compensation expense 13,359   13,359      
Other comprehensive loss (61)     (61)    
Net (loss) income (25,593)       (25,614) 21
Ending Balance at Jun. 30, 2025 179,536 $ 15 1,538,919 73 (1,359,290) (181)
Ending Balance, Shares at Jun. 30, 2025   152,234,772        
Beginning Balance at Dec. 31, 2025 225,001 $ 15 1,581,848 253 (1,363,323) 6,208
Beginning Balance, Shares at Dec. 31, 2025   153,779,418        
Issuance of common stock for cash upon exercise of stock options $ 11,159 $ 1 11,158      
Issuance of common stock for cash upon exercise of stock options, Shares 1,379,053 1,379,053        
Vesting of restricted stock units and market-based restricted stock units   5,352,951        
Share-based compensation expense $ 23,047   23,047      
Repurchase of common stock (25,000)   (25,000)      
Repurchase of common stock, shares   (1,451,800)        
Purchase of capped calls (25,599)   (25,599)      
Capital contributions for Digital Biotechnologies, Inc. 2,475   800     1,675
Other comprehensive loss (465)     (465)    
Net (loss) income (59,956)       (59,821) 135
Ending Balance at Jun. 30, 2026 150,662 $ 16 1,566,254 (212) (1,423,144) 7,748
Ending Balance, Shares at Jun. 30, 2026   159,059,622        
Beginning Balance at Mar. 31, 2026 224,241 $ 16 1,599,708 (28) (1,383,356) (7,901)
Beginning Balance, Shares at Mar. 31, 2026   159,697,221        
Issuance of common stock for cash upon exercise of stock options 6,026   6,026      
Issuance of common stock for cash upon exercise of stock options, Shares   723,267        
Vesting of restricted stock units   90,934        
Share-based compensation expense 11,119   11,119      
Repurchase of common stock (25,000)   (25,000)      
Repurchase of common stock, shares   (1,451,800)        
Purchase of capped calls (25,599)   (25,599)      
Other comprehensive loss (184)     (184)    
Net (loss) income (39,941)       (39,788) (153)
Ending Balance at Jun. 30, 2026 $ 150,662 $ 16 $ 1,566,254 $ (212) $ (1,423,144) $ 7,748
Ending Balance, Shares at Jun. 30, 2026   159,059,622